Declan Doogan

Dr. Doogan is a seasoned drug development executive and life sciences investor with more than 30 years of experience in the global pharmaceutical industry at both major pharmaceutical and biotechnology companies. He joined Pfizer in 1982, where he held a number of senior positions in R&D in the US, UK, and Japan, laterally as the Senior Vice President and Head of Worldwide Development. Since leaving Pfizer in 2007, Dr. Doogan has held executive roles at small pharmaceutical companies, including Amarin Corporation. Beyond his executive career, Dr. Doogan is an investor in emerging biotechnology companies and is a partner at Mediqventures. He serves on the Boards of multiple pharmaceutical companies, including Biohaven Pharmaceuticals where he is a co-founder and Chairman. Dr. Doogan has also held professorships at Harvard School of Public Health, Glasgow University Medical School, and Kitasato University (Tokyo). He received his medical degree from Glasgow University. He is a Fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine and holds a Doctorate of Science from the University of Kent in the UK.